SPEAR pTau 217 outperforms leading ultra-sensitive technology

This application note highlights how SPEAR^® pTau 217, an ultra-sensitive blood-based immunoassay, delivers exceptional performance in Alzheimer’s disease research and clinical studies. Validated across more than 120 clinical plasma samples, SPEAR pTau 217 achieved 98.8% diagnostic accuracy (AUC) and demonstrated a 5.3-fold separation between Alzheimer’s and control populations, outperforming leading ultra-sensitive technologies.